The Role of Private ABS in Esoteric Asset Finance 2024 - Europe | DealCatalyst | TBA, London

With banks retreating from lending under increased regulatory scrutiny and liquidity concerns, originators of non-vanilla financial assets are seeking funding alternatives. Securitization has been a pathway of choice for many of these would-be issuers, but volatility in public markets, scale and infrastructure required, and cost of funds has shut an equal number of borrowers out of the public ABS market. Private credit lenders and arrangers of bespoke private securitizations have entered the funding mix to provide much-needed capital to these non-traditional asset finance companies. This one-day conference will be held in both the US and Europe, each a hotbed of activity. The program will explore the various funding pathways available to finance these unique assets, and investors seeking yield and new opportunities will benefit from an education on these unique assets.

Topics to Be Discussed:
• Esoterics 101: Defining the scope of esoterics: Ligation Finance, High-cost Consumer Loans, Merchant Cash Advance, IP/Entertainment, Life Sciences, Sports and media Finance, Renewables, Franchise/Whole Business, Infrastructure Loans, Data Centers
• Esoteric Assets - are they bankable or not?
• What new and alternative financial assets are emerging?
• How are private funds evaluating these esoteric investments?
• What challenges do non-bank originators in these off-the-run asset classes face when fundraising?
• What is the risk/reward profile for investors willing to conduct the extra due diligence on non-vanilla/exotic assets?
• Private ABS: Incorporating securitization into the private debt financing structure
• Crossover investors: Attracting traditional fixed-income investors to the alternative credit sector i.e. infrastructure ABS deals
• Rating agency views on assessing credit for non-traditional asset types

Who Should Attend
Esoteric Asset Originators (Litigation Finance, IP/ Royalties, Renewables, Infrastructure, Merchant Cash Advance, Life Sciences) • Bank and Non-Bank Direct Lenders • Arrangers of Public and Private ABS Transactions • Institutional Investors (Insurance, Asset Management, Credit/PE Funds) • Broker Dealers • Issuer and Bank Legal Counsel • Rating Agencies • Data and Technology Providers • Trustees